Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on expe...

Descripción completa

Detalles Bibliográficos
Autores principales: Erpenbeck, Veit J., Popov, Todor A., Miller, David, Weinstein, Steven F., Spector, Sheldon, Magnusson, Baldur, Osuntokun, Wande, Goldsmith, Paul, Weiss, Markus, Beier, Jutta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Data Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021787/
https://www.ncbi.nlm.nih.gov/pubmed/27656673
http://dx.doi.org/10.1016/j.dib.2016.08.039
Descripción
Sumario:This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on experimental design and methods on how this data was obtained is also described. Further interpretation and discussion of this data can be found in the article “The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma” (Erpenbeck et al., in press) [1].

Ejemplares similares